Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 2 days ago
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.

Tweaking design may help minimize placebo effects in atopic dermatitis trials

22 Dec 2019

Placebo responses appear to be common in randomized controlled trials (RCTs) for atopic dermatitis (AD), reports a new meta-analysis. Better methodological control, such as double- or triple-blinding and more balanced sex distributions, may help address this.

After applying the selection criteria, 64 RCTs were found to be eligible and were ultimately included in the meta-analysis. Half of the included studies were on adults, and 39.1 percent enrolled children. Studies were retrieved from the databases of Scopus, Lilacs, Great, Embase, Medline and the Cochrane Library.

Most of the studies (81.3 percent; n=52) were double-blinded, 3.1 percent (n=2) were unblinded and 9.4 percent (n=6) did not specify either way. Only over half (57.8 percent; n=37) were specific about the target severity of the population.

There was also great heterogeneity in the outcome measures used. The numerical rating scale or visual analogue scale (NRS/VAS) was employed most commonly, followed by the objective Scoring AD (SCORAD) index and the Eczema Area Severity Index (EASI). The Dermatology Life Quality Index was also used, as were different laboratory tests.

Multivariable mixed models of Cohen’s D found that the effect sizes of EASI scores increased in the placebo arms of studies with more males. The same was true for effect sizes of NRS/VAS.

Study design also appeared to be an important consideration for placebo effects. The effect-sizes of EASI in the placebo group were lower in studies that were double- or triple-blinded. Those with concomitant prescription of topical therapies, on the other hand, saw greater effects of EASI and NRS/VAS in placebo groups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 2 days ago
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.